carnitine palmitoyltransferase 2
अंतिम अद्यतन 17 Mar 2025
मरीज की संपादकीय दिशानिर्देशों
- डाउनलोडडाउनलोड
- साझा करें
- Language
- चर्चा
- Ask Patient
- ऑडियो संस्करण
- Google पर पसंदीदा स्रोतों में जोड़ें
The CPT2 gene provides instructions for making an enzyme called carnitine palmitoyltransferase 2. This enzyme is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. Fatty acids are a major source of energy for the heart and muscles. During periods of fasting, fatty acids are also an important energy source for the liver and other tissues.
के लिए वीडियो चयन Genesवीडियो लाइब्रेरी
Normal function
The CPT2 gene provides instructions for making an enzyme called carnitine palmitoyltransferase 2. This enzyme is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. Fatty acids are a major source of energy for the heart and muscles. During periods of fasting, fatty acids are also an important energy source for the liver and other tissues.
Within liver cells, fatty acid oxidation takes place within mitochondria, which are the energy-producing centers in cells. Before they can enter mitochondria, a group of fats called long-chain fatty acids must first attach to a compound called carnitine. Once inside mitochondria, carnitine palmitoyltransferase 2 removes the carnitine from these fatty acids and adds a substance called coenzyme A. Long-chain fatty acids must be joined to coenzyme A before they can be metabolized to produce energy.
Conditions referring to this gene or chromosome
Other names
CPT II
CPT2_HUMAN
CPTASE
Related patient information and medicines

Patient information leaflet
टाइप 2 मधुमेह का उपचार
If you have CKD and have high levels of albumin in your urine (an albumin creatinine ratio (ACR)... Dipeptidyl. Incretins are chemicals which are produced by the gut (intestine) in response to food. Incretins: Help keep you feeling full; and Enhance your body's production of insulin; and Reduce production of another hormone, glucagon, which raises.

Patient information leaflet
मधुमेह
There are two main types of मधुमेह - type 1 मधुमेह and type 2 diabetes. Find out more here: [/health/diabetes-mellitus-leaflet](https://patient.info/health/diabetes-mellitus-leaflet) मधुमेह mellitus (just called diabetes from now on) occurs when the level of sugar (glucose) in the blood is higher than normal. If.

Patient information leaflet
ग्रंथि ज्वर
Glandular. Although it can make some people feel quite ill, full recovery is usual. What is glandular fever. ग्रंथि ज्वर है a viral infection, mostly caused by the Epstein-Barr virus. The virus can be passed from person to person by close contact. Glandular fever is known as infectious mononucleosis in the US and some other countries. This is.

Patient information leaflet
टाइप 2 मधुमेह
टाइप 2 मधुमेह can occur at any age, including during childhood, but it occurs mainly in people aged over 40. The first-line treatment is diet, weight control and physical activity. Other treatments include reducing blood pressure if it is high, lowering high cholesterol levels, and also... This is called insulin resistance. You can learn more.

Patient information leaflet
टाइप 2 मधुमेह आहार
यह first-line treatment के लिए टाइप 2 मधुमेह involves making changes to your lifestyle, through diet, weight control and physical activity. Regular check-ups Type 2 diabetes and medication for diabetes (whether in tablet or injection form) definitely aren't the only way to control your blood sugar (glucose) levels. Dr Partha Kar The first-line.

Patient information leaflet
गले में खराश
A sore throat is common and usually goes after a few days. Simple treatments such as taking paracetamol and keeping hydrated can help ease pain. This leaflet explains the causes and treatment of sore throats. Key points A sore throat is pain or irritation in the back of the throat that is often worse when swallowing. It is usually caused by viral.
अधिक पठन और संदर्भ
- carnitine palmitoyltransferase 2; MedlinePlus, National Library of Medicine.
- Corti S, Bordoni A, Ronchi D, Musumeci O, Aguennouz M, Toscano A, Lamperti C, Bresolin N, Comi GP. Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency. J Neurol Sci. 2008 Mar 15;266(1-2):97-103. doi: 10.1016/j.jns.2007.09.015. Epub 2007 Oct 23.
- Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol. 2005 Jan;62(1):37-41. doi: 10.1001/archneur.62.1.37.
- Illsinger S, Lucke T, Peter M, Ruiter JP, Wanders RJ, Deschauer M, Handig I, Wuyts W, Das AM. Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening. Am J Med Genet A. 2008 Nov 15;146A(22):2925-8. doi: 10.1002/ajmg.a.32545.
- Isackson PJ, Bennett MJ, Lichter-Konecki U, Willis M, Nyhan WL, Sutton VR, Tein I, Vladutiu GD. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab. 2008 Aug;94(4):422-427. doi: 10.1016/j.ymgme.2008.05.002. Epub 2008 Jun 11.
- Joshi PR, Zierz S. Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules. 2020 Apr 13;25(8):1784. doi: 10.3390/molecules25081784.
- Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):77-85. doi: 10.1002/ajmg.c.30087.
- LoPiccolo MK, Vockley J. Carnitine Palmitoyltransferase II Deficiency. 2004 Aug 27 [updated 2026 Apr 9]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1253/
- Olpin SE, Afifi A, Clark S, Manning NJ, Bonham JR, Dalton A, Leonard JV, Land JM, Andresen BS, Morris AA, Muntoni F, Turnbull D, Pourfarzam M, Rahman S, Pollitt RJ. Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. J Inherit Metab Dis. 2003;26(6):543-57. doi: 10.1023/a:1025947930752.
- Orngreen MC, Duno M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M, Vissing J. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005 Jan;57(1):60-6. doi: 10.1002/ana.20320.
- Ramsay RR, Zammit VA. Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med. 2004 Oct-Dec;25(5-6):475-93. doi: 10.1016/j.mam.2004.06.002.
- Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. Lab Invest. 2003 Nov;83(11):1543-54. doi: 10.1097/01.lab.0000098428.51765.83.
हमारे में दूसरों के साथ अपने विचार या अनुभव साझा करें रोगी समुदायों.
पेशेंट न्यूज़लेटर के लिए साइन अप करें
आपकी साप्ताहिक खुराक स्पष्ट, विश्वसनीय स्वास्थ्य सलाह की - जो आपको सूचित, आत्मविश्वासी और नियंत्रण में महसूस करने में मदद करने के लिए लिखी गई है।.
सदस्यता लेने पर आप हमारी स्वीकार करते हैं गोपनीयता नीति. आप किसी भी समय सदस्यता समाप्त कर सकते हैं। हम कभी भी आपका डेटा नहीं बेचते।.

